Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00899847 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00899847: Completed Phase 2 study, sponsored by Stanford University.
NCT00899847 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00899847, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
To evaluate the toxicity and tolerability of this tandem autologous/allogeneic transplant approach for patients with advanced stage multiple myeloma.
Interventions
- DRUG Cyclophosphamide
- DRUG Melphalan
- DRUG Filgrastim
- PROCEDURE Autologous peripheral blood stem cells (auto-PBSC) transplantation
- PROCEDURE Allogeneic peripheral blood stem cells (allo-PBSC) transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2009-05 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00899847
The ClinicalTrials.gov registry entry for NCT00899847 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00899847 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00899847 about?
NCT00899847 is a clinical study titled "Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG". To evaluate the toxicity and tolerability of this tandem autologous/allogeneic transplant approach for patients with advanced stage multiple myeloma.
What is the current status of trial NCT00899847?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2009-05. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00899847?
The interventions under investigation include: Cyclophosphamide (DRUG), Melphalan (DRUG), Filgrastim (DRUG), Autologous peripheral blood stem cells (auto-PBSC) transplantation (PROCEDURE), Allogeneic peripheral blood stem cells (allo-PBSC) transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00899847?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.